Program
Cyproterone Acetate
Also written as “Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)”, “Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg” and “Cyproterone acetate”.
Its studies are mostly in Acne Vulgaris · Adenocarcinoma · Hot Flashes, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eurofarma Laboratorios | 22 open or running | phase 3since Mar 25, 2025 | Mar 25, 2025 | Feb 2027phase 3 · NCT06905210 |
| Takeda | 10 open or running | phase 3since Nov 3, 2009 | Nov 3, 2009 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since May 2, 2000 | May 2, 2000 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 2, 2000First study: phase 3 study in Hot FlashesNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00005623 · United States
- Nov 3, 2009Takeda's first study: phase 3 study in AdenocarcinomaNew to TakedaTakeda · NCT01011751 · 311 enrolled · France
- Mar 25, 2025Eurofarma Laboratorios's first study: phase 3 study in Acne VulgarisNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT06905210 · 531 planned · Brazil
- Jul 15, 2026Phase 3 study in ContraceptionEurofarma Laboratorios · NCT07714616 · 1,600 planned · Brazil
Ahead
- Feb 2027Primary completion: phase 3 study in Acne VulgarisEurofarma Laboratorios · NCT06905210
- May 31, 2029Primary completion: phase 3 study in ContraceptionEurofarma Laboratorios · NCT07714616
TargetBeta
“Androgen Receptor antagonist; Glucocorticoid receptor antagonist; Progesterone receptor agonist”ChEMBL 37, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07714616Contraception · Brazil | 3 | Not yet recruiting | Eurofarma Laboratorios | May 31, 2029 | 1,600 |
| NCT06905210Acne Vulgaris · Brazil | 3 | Recruiting | Eurofarma Laboratorios | Feb 2027 | 531 |
| NCT01011751Adenocarcinoma · France | 3 | Completed | Takeda | Dec 2007 | 311 |
| NCT00005623Hot Flashes · United States | 3 | Completed | Teva Pharmaceutical Industries |
How it is read
Names in the registry
- “Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg)”, 1 entry
- “Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg”, 1 entry
- “Cyproterone acetate”, 1 entry
- “cyproterone acetate”, 1 entry
Conditions, from the studies’ own filings
- Acne Vulgaris, 1 study
- Adenocarcinoma, 1 study
- Hot Flashes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.